A thoughtfully developed tracker can provide deep insights on any therapeutic area. Using the results of a syndicated APLUSA tracking study on the multiple myeloma market, this series of blog posts look at the key insights that such a tracking study can provide.

A tracking study often addresses questions on market dynamics. Insights on the evolution of the market are key to your company and serve to advance your understanding beyond the knowledge of your competitors. In this post, we look at examples of top-5 EU MM market dynamics, as revealed by our syndicated MM tracking study.

Dynamic Patient Share

How will brand and regimen patient shares change in the future?

Dynamic patient share is the brand shares of recent as opposed to all patients, and measuring these shares provides key insights for the near future of the market. First-line MM induction pre-SCT, maintenance, and non-SCT shares are generally stable in the top 5 EU. Indications of change, however, are evident in individual countries.

Regardless of total patient share, an upward trend in the brand share of recent patients suggests that a product is growing and that its overall share will increase in the near to mid-term future. A downward trend of recent patients suggests that a product is declining. Outside of clinical trials, slightly more than one-third of all patients recently began drug treatment.

Are there by-country differences within the top-5 EU?

First-line dynamic share data from the top-5 EU marketplace suggests the following: In France Thalidomide-combinations are growing across all first-line indications, while there is no apparent decrease in later-lines. In Germany, Thalidomide is losing first-line maintenance share to both Revlimid® (lenalidomide)and Velcade® (bortezomib). In Italy, dynamic share data shows that the combination of Revlimid® and Velcade® is growing in first-line non-SCT patients. In Spain, Thalidomide’s first-line induction share is increasing at the expense of Revlimid®. In the UK, Velcade® and Thalidomide combinations with Revlimid® are decreasing in the first-line maintenance setting, while Revlimid® overall remains steady.

Key observations on how patients sequence brands from line to line of treatment in the top-5 EU MM market?

• More than 40% of SCT patients receiving Velcade® in the first line receive Revlimid® in second line.
• One-third of second line Revlimid® patients switch to Imnovid® (pomalidomide) in the third line and a similar percentage switch to Darzalex® (daratumumab). Almost half of second line Velcade® patients switch to Revlimid® in the third line.
• More than 40% of top-5 EU third line Revlimid® patients switch to Imnovid® in fourth and later lines. Also, approximately 70% of third line Imnovid® patients receive Darzalex® in fourth and later lines.